EA201990715A1 - Стабилизирующие тример мутации белка оболочки hiv - Google Patents

Стабилизирующие тример мутации белка оболочки hiv

Info

Publication number
EA201990715A1
EA201990715A1 EA201990715A EA201990715A EA201990715A1 EA 201990715 A1 EA201990715 A1 EA 201990715A1 EA 201990715 A EA201990715 A EA 201990715A EA 201990715 A EA201990715 A EA 201990715A EA 201990715 A1 EA201990715 A1 EA 201990715A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
envelope proteins
protein
mutations
hiv envelope
Prior art date
Application number
EA201990715A
Other languages
English (en)
Inventor
Люси Рюттен
Дафне Трюан
Ника Минди Строкаппе
Йоханнес Петрус Мария Лангедейк
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA201990715A1 publication Critical patent/EA201990715A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Представлены белки оболочки вируса иммунодефицита человека (HIV), имеющие мутации, которые стабилизируют тримерную форму белка оболочки. Белки оболочки HIV имеют определенные аминокислотные замены в указанных положениях последовательности белка оболочки. Белки оболочки HIV, описанные в данном документе, характеризуются увеличенной процентной долей образования тримеров и/или увеличенным выходом тримеров по сравнению с белком оболочки HIV, который не имеет одну или более из указанных аминокислотных замен. Также представлены молекулы нуклеиновой кислоты и векторы, кодирующие белки оболочки HIV, а также композиции, содержащие белки оболочки HIV, нуклеиновую кислоту и векторы.
EA201990715A 2016-09-15 2017-09-14 Стабилизирующие тример мутации белка оболочки hiv EA201990715A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188866 2016-09-15
PCT/EP2017/073141 WO2018050747A1 (en) 2016-09-15 2017-09-14 Trimer stabilizing hiv envelope protein mutations

Publications (1)

Publication Number Publication Date
EA201990715A1 true EA201990715A1 (ru) 2019-08-30

Family

ID=57017955

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990715A EA201990715A1 (ru) 2016-09-15 2017-09-14 Стабилизирующие тример мутации белка оболочки hiv

Country Status (30)

Country Link
US (3) US10793607B2 (ru)
EP (2) EP3512543B1 (ru)
JP (2) JP7178344B2 (ru)
KR (1) KR102513146B1 (ru)
CN (1) CN109689091A (ru)
AR (1) AR109528A1 (ru)
AU (2) AU2017327672B2 (ru)
BR (1) BR112019004593A2 (ru)
CA (1) CA3036959A1 (ru)
CY (1) CY1124518T1 (ru)
DK (1) DK3512543T3 (ru)
EA (1) EA201990715A1 (ru)
ES (1) ES2824525T3 (ru)
HR (1) HRP20201458T1 (ru)
HU (1) HUE052008T2 (ru)
IL (2) IL294832A (ru)
LT (1) LT3512543T (ru)
MA (1) MA46230B1 (ru)
MD (1) MD3512543T2 (ru)
MX (1) MX2019002938A (ru)
MY (1) MY190534A (ru)
PH (1) PH12019500280A1 (ru)
PL (1) PL3512543T3 (ru)
PT (1) PT3512543T (ru)
RS (1) RS60919B1 (ru)
SG (2) SG11201901206SA (ru)
SI (1) SI3512543T1 (ru)
TW (1) TWI742158B (ru)
WO (1) WO2018050747A1 (ru)
ZA (1) ZA201901597B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
JP7046832B2 (ja) * 2016-05-02 2022-04-04 ザ スクリプス リサーチ インスティテュート Ｈｉｖ－１免疫原に関連した組成物および方法
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
BR112019004593A2 (pt) 2016-09-15 2019-07-02 Janssen Vaccines & Prevention Bv mutações da proteína do envelope do hiv estabilizando o trímero
CA3039089A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
EP3638302B1 (en) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
WO2019016062A1 (en) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM
AU2019285048B2 (en) 2018-06-13 2023-06-08 The Scripps Research Institute Nanoparticle vaccines with novel structural components
EA038287B1 (ru) * 2018-06-18 2021-08-04 Янссен Вэксинс Энд Превеншн Б.В. Стабилизирующие тример мутации белка оболочки hiv
CA3114870A1 (en) * 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
US20220106610A1 (en) * 2019-01-22 2022-04-07 Bluebird Bio, Inc. Methods and systems for manufacturing viral vectors
CN110184298B (zh) * 2019-05-15 2023-05-16 武汉璟泓科技股份有限公司 Hiv突变型表面糖蛋白及其纳米化抗原与制备方法
US20220401546A1 (en) * 2019-11-14 2022-12-22 Emory University HIV Immunogens, Vaccines, and Methods Related Thereto
EP4245767A1 (en) * 2020-11-12 2023-09-20 Xiamen University Modified membrane protein of human immunodeficiency virus and use thereof
AR124937A1 (es) 2021-02-23 2023-05-24 Janssen Vaccines & Prevention Bv Mutación estabilizante de trímeros de proteínas de la envoltura del vih
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2023192835A1 (en) * 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2024091921A1 (en) * 2022-10-24 2024-05-02 Duke University Stabilization of human immunodeficiency virus (hiv) envelopes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
AU2002231639B2 (en) 2000-11-23 2007-01-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant
CA2466413C (en) 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
EP2371387A3 (en) * 2003-09-17 2012-01-25 Duke University HIV consensus sequence antigens and their use in vaccina
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
NZ553889A (en) 2004-10-13 2009-11-27 Crucell Holland Bv Replication-defective adenovirus comprising a chimeric hexon protein and replaced hypervariable ragions HVR1-7
CN1857345B (zh) * 2005-05-08 2010-09-01 谢秀琼 一种治疗偏头痛的药物组合物及其制备方法
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERIC HIV ENV PROTEINS AND USES THEREOF
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
HUE037270T2 (hu) 2008-10-10 2018-08-28 Childrens Medical Center Biokémiailag stabilizált HIV-1 ENV trimer vakcina
ES2699685T3 (es) 2008-11-18 2019-02-12 Beth Israel Deaconess Medical Ct Inc Vacunas antivíricas con inmunogenicidad celular mejorada
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
JP5783642B2 (ja) 2010-01-28 2015-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体
EP2611465A4 (en) 2010-08-31 2014-06-04 Theraclone Sciences Inc NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
SG11201503864TA (en) 2012-11-16 2015-06-29 Beth Israel Hospital Recombinant adenoviruses and use thereof
AU2014203886B2 (en) 2013-01-07 2017-11-02 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10400015B2 (en) * 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
EA037583B1 (ru) 2014-09-26 2021-04-16 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
BR112019004593A2 (pt) * 2016-09-15 2019-07-02 Janssen Vaccines & Prevention Bv mutações da proteína do envelope do hiv estabilizando o trímero
WO2019016062A1 (en) * 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM

Also Published As

Publication number Publication date
DK3512543T3 (da) 2020-10-12
EP3512543B1 (en) 2020-07-22
JP2019534690A (ja) 2019-12-05
MD3512543T2 (ro) 2020-11-30
US11820796B2 (en) 2023-11-21
IL265186A (en) 2019-05-30
US20200369731A1 (en) 2020-11-26
HRP20201458T1 (hr) 2020-12-11
BR112019004593A2 (pt) 2019-07-02
JP7178344B2 (ja) 2022-11-25
ZA201901597B (en) 2022-12-21
US20180072777A1 (en) 2018-03-15
AU2017327672B2 (en) 2020-10-15
US10793607B2 (en) 2020-10-06
WO2018050747A1 (en) 2018-03-22
TWI742158B (zh) 2021-10-11
PL3512543T3 (pl) 2021-01-11
AU2017327672A1 (en) 2019-02-28
HUE052008T2 (hu) 2021-04-28
CN109689091A (zh) 2019-04-26
AU2020267278B2 (en) 2023-07-20
CA3036959A1 (en) 2018-03-22
TW201819401A (zh) 2018-06-01
MA46230A (fr) 2019-07-24
JP2023011941A (ja) 2023-01-24
CY1124518T1 (el) 2022-03-24
RS60919B1 (sr) 2020-11-30
NZ750773A (en) 2021-02-26
AU2020267278A1 (en) 2020-12-10
ES2824525T3 (es) 2021-05-12
SI3512543T1 (sl) 2020-10-30
US20220315627A1 (en) 2022-10-06
US11365222B2 (en) 2022-06-21
EP3747463A1 (en) 2020-12-09
MX2019002938A (es) 2019-10-15
MA46230B1 (fr) 2020-10-28
KR102513146B1 (ko) 2023-03-23
SG11201901206SA (en) 2019-04-29
IL265186B (en) 2022-09-01
IL294832A (en) 2022-09-01
EP3512543A1 (en) 2019-07-24
AR109528A1 (es) 2018-12-19
PH12019500280A1 (en) 2019-10-28
SG10202001956UA (en) 2020-04-29
LT3512543T (lt) 2020-11-10
KR20190050786A (ko) 2019-05-13
MY190534A (en) 2022-04-27
PT3512543T (pt) 2020-10-13

Similar Documents

Publication Publication Date Title
EA201990715A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
EA202090817A1 (ru) Триспецифические белки и способы их применения
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
EA201890999A1 (ru) Вакцина против вируса простого герпеса
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201991798A1 (ru) Стабильные при хранении составы
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MX2019007924A (es) Vacunas contra la influenza.
EA202190522A1 (ru) Стабилизированные тримеры гликопротеина филовируса
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
AR112339A1 (es) Mutaciones de proteína de envoltura de vih que estabilizan trímeros
EA202092694A1 (ru) Системы и способы количественного определения и модификации вязкости белков
EA201992558A1 (ru) Варианты белка bmp7 человека